Medpace Q1 2026: Smashing Expectations
from The Daily News Now! Business
Medpaces Q1 2026 results exceeded expectations with $706.6 million in revenue, a 26.5% increase from last year, and EPS of $4.28, surpassing forecasts by 10.2%. The company maintained full-year guidance and solid margins, with organic sales growth of 25.8% driven by strong demand for core clinical trial services. Despite a slight margin dip, share buybacks boosted EPS growth, but shares fell 19.8% to $408 due to investor disappointment. Support the show: Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN: [email protected] This is an automated, high-level news summary based on public reporting. Report issues to [email protected]. View sources & latest updates: https://sources.thednn.ai/7f42f7e2d5389b2c
Embed this episode
No transcript yet.